Cantor Fitzgerald resumed coverage on DiaMedica Therapeutics
$DMAC
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald resumed coverage of DiaMedica Therapeutics with a rating of Overweight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/14/2025 | Overweight | Cantor Fitzgerald | |
| 10/30/2025 | Buy | TD Cowen | |
| 10/7/2024 | $7.00 | Buy | H.C. Wainwright |
| 4/24/2024 | $8.00 | Buy | Craig Hallum |
| 6/22/2023 | $7.00 | Perform → Outperform | Oppenheimer |
| 6/30/2021 | $38.00 → $32.00 | Buy | Roth Capital |
10-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)
SCHEDULE 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)
8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)
Received Regulatory Approval from Health Canada Supporting Initiation of Phase 2 DM199 Study in Early-onset Preeclampsia. DM199 Preeclampsia Phase 2 Investigator-Sponsored Trial (IST) Part 1a Expansion Cohort Enrolling, Completion Expected in 1H 2026. ReMEDy2 Phase 2/3 AIS Trial of DM199 Approaching 70% of Required Interim Enrollment; Interim Analysis planned 2H 2026. $60 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2H 2027. Conference Call and Webcast on March 31 at 8:00 AM ET / 7:00 AM CT. DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its full-year 2025 financial results will be released after the markets close on Monday, March 30th. DiaMedica will host a live conference call on Tuesday, March 31st at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Tuesday, March 31, 2026 Time: 7:00 AM CDT / 8:00 AM EDT Web access: https://app.webinar.net/bxPLk6nkE0q Dial In: (646) 357-8766 Confe
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in three upcoming investment bank conferences. Details TD Cowen 46th Annual Healthcare Conference Boston, Massachusetts Fireside chat with Rick Pauls, CEO, and Julie Krop, M.D., Chief Medical Officer, on Monday, March 2, 2026, at 11:50 a.m. Eastern Time (ET) Barclays 28th Annual Global Healthcare Conference Miami, Florida Fireside chat with Rick Pauls, CEO on Wednesday, March 10, 2026, at 10:00 a.m. ET Leerink Partners Global Health
Cantor Fitzgerald resumed coverage of DiaMedica Therapeutics with a rating of Overweight
TD Cowen initiated coverage of DiaMedica Therapeutics with a rating of Buy
H.C. Wainwright initiated coverage of DiaMedica Therapeutics with a rating of Buy and set a new price target of $7.00
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
SC 13G - DiaMedica Therapeutics Inc. (0001401040) (Subject)
SC 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)
SC 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the appointment of Julie Krop, MD, as Chief Medical Officer (CMO), effective immediately. Dr. Krop will succeed Dr. Lorianne Masuoka, who has resigned from her position as CMO for personal reasons. "We are pleased to welcome Dr. Krop to our executive leadership team," said Rick Pauls, President and CEO of DiaMedica. "Her extensive experience in the biopharma industry and track record of advancing innovative therapeutics from proof of concept to approval will be invaluable to our te
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of Daniel J. O'Connor to its Board of Directors, effective February 20, 2025. Mr. O'Connor has decades of executive experience and leadership in the biopharmaceutical industry, including as CEO and other executive level leadership positions at Ambrx Biopharma, Inc. (Ambrx), ImClone Systems Incorporated, Bracco Diagnostics, and PharmaNet (today, Syneos Health). Mr. O'Connor has gained a reputation as a seasoned and successful biopharma CEO, most recently serving as President, Chief Executive Officer and Director of Ambrx, wher
Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh
Received Regulatory Approval from Health Canada Supporting Initiation of Phase 2 DM199 Study in Early-onset Preeclampsia. DM199 Preeclampsia Phase 2 Investigator-Sponsored Trial (IST) Part 1a Expansion Cohort Enrolling, Completion Expected in 1H 2026. ReMEDy2 Phase 2/3 AIS Trial of DM199 Approaching 70% of Required Interim Enrollment; Interim Analysis planned 2H 2026. $60 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2H 2027. Conference Call and Webcast on March 31 at 8:00 AM ET / 7:00 AM CT. DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its full-year 2025 financial results will be released after the markets close on Monday, March 30th. DiaMedica will host a live conference call on Tuesday, March 31st at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Tuesday, March 31, 2026 Time: 7:00 AM CDT / 8:00 AM EDT Web access: https://app.webinar.net/bxPLk6nkE0q Dial In: (646) 357-8766 Confe
Preeclampsia Phase 2 IST Trial: Part 1a Dose Escalation Cohort Complete with Expansion Cohort Now Enrolling; Screening for Part 3, Fetal Growth Restriction Cohort, Expected to Start in Coming Weeks Held in Person pre-IND meeting with U.S. FDA to Discuss Plans for the Initiation of a U.S. Phase 2 DM199 Study in Preeclampsia AIS enrollment in ReMEDy2 Phase 2/3 Trial Nearing 50% of Target of 200 Patients for the Interim Analysis Expected in 2H 2026 $55 million in Cash, Cash Equivalents and Investments, Anticipated Runway into 2H 2027 Conference Call and Webcast on November 13 at 8:00 AM ET / 7:00 AM CT DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutica